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1.1. Structure and Membership of the Writing Committee
Members of the Writing Committee included experienced
clinicians and specialists in cardiology, cardiac rehabili-
tation, quality improvement, outcomes research, epide-
miology, and performance measures (PMs) methodology,
as well as patient advocates. The Writing Committee
also included representatives from the American Associ-
ation for Cardiovascular and Pulmonary Rehabilitation
(AACVPR), the American Academy of Family Physicians
(AAFP), the American Medical Association–Physician
Consortium for Performance Improvement (AMA-PCPI),
the American Nurses Association (ANA), the American
Society of Health-System Pharmacists (ASHP), the
National Committee for Quality Assurance (NCQA), and
Mended Hearts, Inc.
1.2. Disclosure of Relationships With Industry
The American College of Cardiology (ACC)/American
Heart Association (AHA) Task Force on Performance
FIGURE 1 The Interdependencies of Shared Accountability in
Performance Measurement
QI indicates quality improvement; and SES, socioeconomic status.
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2135Measures makes every effort to avoid actual, potential, or
perceived conﬂicts of interest that may arise as a result
of relationships with industry or other entities. The work
of the Writing Committee was supported exclusively by
the ACC and the AHA, without commercial support. The
Writing Committee members volunteered their time. All
members of the Writing Committee, as well as those
selected to serve as peer reviewers of this document, were
required to disclose all current relationships and those
existing within the 12 months before the initiation of the
project. It was also required that the Writing Committee
co-chairs and at least 50% of the Writing Committee have
no relevant relationships with industry or other entities.
Because the Writing Committee is deﬁning general prin-
ciples, rather than making speciﬁc PM recommendations,
members’ relationships with pharmaceutical and device
companies were not considered relevant to the topic.
Author and peer reviewer relationships with industry
and other entities relevant to the document are included
in Appendices 1 and 2. Additionally, to ensure complete
transparency, the writing committee members’ compre-
hensive disclosure information, including RWI not rele-
vant to the present document, is available as an online
supplement. Disclosure information for the Task force is
available as a separate online supplement.
2. THE NEED FOR SHARED ACCOUNTABILITY
PMs have been useful for measuring the quality of care,
promoting accountability for care, and improving the
care and outcomes for patients with acute and chronic
medical conditions (1,2). To date, the conceptualization
of PMs has generally been “clinician focused,” developed
to help deﬁne the quality of care delivered by clinicians
(both individually and collectively); however, the ulti-
mate goal of performance measurement and assessment
is to improve patient outcomes, including health status
(quality of life, symptom burden, and functional status),
morbidity, and mortality. Patient participation and en-
gagement are integral to the success of any treatment
plan. Disease treatment and health promotion activities
typically require action from multiple parties, including
clinicians, the broader healthcare team, and the system in
which health care is delivered, as well as patients, family
members, caregivers, and community-based support ser-
vices. It is clear that patients who are actively engaged in
self-care, deﬁned as the ability to perform the activities
necessary to achieve, maintain, or promote optimal
health, are more likely to successfully achieve their
treatment goals (3).
The Institute of Medicine has advocated for “shared
accountability,” in which all stakeholders within the
healthcare system and all members of the healthcare
team(s), including the patient, are responsible for andcontribute to the success of any measure (4). Underpin-
ning this concept is recognition that the actions of clini-
cians and the patient are not independent but rather
inextricably linked. Although the locus of control for
treatment adherence and self-care is typically attributed
to the patient, this can be inﬂuenced by patient factors
(e.g., health literacy, sociocultural factors, economic
limitations), clinician factors (e.g., skills in patient edu-
cation, effective therapeutic communication, cultural
competency, follow-up reinforcement), and healthcare
system factors (e.g., access to needed care, communica-
tion among caregivers, medication coverage, costs).
These intricate interdependencies help illustrate the
rationale for adopting the concept of shared account-
ability when PMs are under consideration (Figure 1). Note,
here and throughout the document, the term “clinician”
is meant to include not only physicians, but also the
entire healthcare team (e.g., nurses, pharmacists, physical
therapists, social workers) and the systems of care in
which the clinician works (e.g., clinics, hospitals, health
systems).
In the context of a shared PM, the concept of shared
accountability must be deﬁned, particularly as it relates to
measure attribution. For many years, the nation’s quality
and performance organizations have tracked clinician
performance. Clinicians and hospitals have been held
accountable for instituting evidence-based processes of
care. Increasingly, PMs are being extended to evaluate
whether patients follow prescribed care plans, as well
as whether patients’ longitudinal health outcomes are
improved. PMs are also increasingly being tied to impor-
tant consequences, such as clinician ranking, reputation,
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2136and differential reimbursement (5). Nevertheless, the ac-
tions of clinicians can inﬂuence patients’ behavior and
vice versa, and clinicians and patients together affect
the outcome of the PM. These interdependencies are
rarely incorporated into current PMs. The consequences
of failing to meet the metrics of a PM are attributed to
the clinician alone, even though patient behavior, sys-
tem characteristics, and other healthcare team members
contribute to success or failure.
This document will address the following issues related
to shared-accountability PMs: 1) the deﬁnition, rationale,
and scope; 2) examples of existing measures; 3) method-
ological challenges; 4) factors affecting feasibility; and
5) potential beneﬁcial and adverse consequences.
3. SHARED ACCOUNTABILITY AND PMS
3.1. General Overview
Figure 2 depicts the continuum of healthcare delivery (6).
Clinicians must make the correct diagnosis, educate the
patient on the diagnosis, engage the patient in jointly
developing an appropriate treatment plan, monitor
progress, and ensure the patient has appropriate support
for self-care. Clinician follow-up should include assessing
the patient’s response to treatment, making adjustments
in the treatment plan as appropriate, and ensuring
continuation of appropriate monitoring and support for
self-care.
The general framework of shared accountability is
predicated on partnerships between patients and clini-
cians, in which patients play an active role in setting
goals, making treatment decisions, and assessing out-
comes. Ideally, patients would be aware of what to watch
for, contact their clinicians when symptoms arise, learn
about their condition and what they can do to improve
their health, implement agreed-on treatment plans and
lifestyle changes, and follow up with their clinicians toFIGURE 2 A Multistep Framework of Continuity of Health Care (6)
Arrows represent the necessary steps in the continuity of care, ultimately leading
person(s) responsible for each step. Adapted from Spertus et al. (6).assess outcomes and adjust the treatment plan. In this
iterative process, the clinician, healthcare system, pa-
tient, and family members work together, with the end
goal of improving patient-centered outcomes (symptoms,
functional status, and quality of life), morbidity, and
mortality. Clinicians and the healthcare system should
facilitate this process by ensuring that patients have suf-
ﬁcient support and knowledge to actively participate in
their health care. Key conceptual issues for shared
accountability include 1) shared goal setting; 2) shared
decision making; 3) shared care planning and monitoring,
including patient feedback and self-care; and 4) assess-
ment of patients’ longitudinal outcomes.
3.2. Examples of Shared-Accountability Measures
In this section, we provide a few examples of current PMs
and then discuss how the concept of shared account-
ability can be incorporated or made more explicit.
3.2.1. Longitudinal Process Adherence
Traditionally, process PMs have focused on acute condi-
tions and have been cross sectional, measuring care
delivered at a point in time or over a relatively short
period of time. However, it is increasingly recognized
that a longitudinal timeline should be considered for
PMs. The reasons for this are 2-fold. To be effective, most
treatments need to be delivered consistently over time.
Additionally, we have a growing body of evidence that
longitudinal treatment adherence is quite poor. For ex-
ample, although beta blockers are prescribed for 95% of
patients at hospital discharge after an acute myocardial
infarction, almost one half of patients will no longer be
adherent to beta blockers by 6 months, even among
employed populations with medication coverage (7).
Achieving (or failing to achieve) longitudinal medica-
tion adherence is a shared responsibility. The discharging
clinician should discuss with patients their preferencesto the patient’s outcome. Rounded boxes preceding the arrows indicate the
J A C C V O L . 6 4 , N O . 2 0 , 2 0 1 4 Peterson et al.
N O V E M B E R 1 8 / 2 5 , 2 0 1 4 : 2 1 3 3 – 4 5 Clinician-Patient Shared Accountability in Performance Measures
2137for treatment, prescribe the appropriate medications, and
educate patients about the effects and side effects of the
medication and the importance of medication adherence.
The patient should ﬁll the prescription, take the medica-
tion as prescribed, and call the clinician if adverse effects
occur. In addition, at follow-up, the outpatient clinician
must review these prescribed medications and the pa-
tient’s experience with taking the medications and make
appropriate modiﬁcations that reﬂect up-to-date evi-
dence and clinical practice guidelines, as well as the pa-
tient’s experience with the medication. Clinicians, family
members, and caregivers can all play important roles in
understanding and supporting medication adherence.
These activities are not performed in isolation. Each of
these parties can indirectly inﬂuence the others, which
may increase or decrease longitudinal adherence. To in-
crease the likelihood of adherence to medication pre-
scribed at hospital discharge, a clinician can select an
affordable medication or one speciﬁcally covered by the
patient’s formulary. Additionally, both inpatient and
outpatient clinicians should provide patients and their
caregivers with sufﬁcient information on why adherence
is important and should query them about their concerns
and any real or potential barriers to adherence at initial
prescription and at each patient encounter.
3.2.2. Intermediate Patient Outcome Metrics—
Reaching Target Goals (Blood Pressure, Hemoglobin A1c)
PMs have traditionally been limited in scope to the eval-
uation of speciﬁc processes of care. Many assess whether
a clinician prescribed a medication to treat a speciﬁc
cardiac risk factor, without measuring whether the impact
of the drug or target goal was achieved (e.g., angiotensin-
converting enzyme inhibitors for patients with left ven-
tricular dysfunction). Some PMs address only whether an
intermediate outcome was achieved. For treatment of
hypertension, current PMs assess whether blood pressure
(BP) was measured and whether BP goals were achieved
(e.g., BP <140/90 mm Hg). This might be acceptable in a
setting in which the BP goal was reached; however, in
settings in which the BP goal was not achieved, it would
be informative to have other process measures, such as
treatment intensiﬁcation or alteration by clinician(s) in
response to elevated BP levels (8).
In this example, the success of achieving the interme-
diate outcome is a shared responsibility, dependent on
multiple parties. The patient ﬁrst seeks care from a
clinician to obtain a diagnosis of hypertension; the clini-
cian must recognize when treatment is required and
prescribe the appropriate medication. Then the patient
purchases the medication, takes it as prescribed, and
follows up with the clinician to convey his or her experi-
ence with taking the medication and to report beneﬁts
and any adverse side effects. This may involve homemonitoring of BP to assess whether the BP is controlled
throughout the day. If the ﬁrst medication choice or dose
titration does not achieve the desired goal, several itera-
tions of this process will be required. If the patient is
followed by several clinicians, each of whom could
reasonably be considered responsible for treating BP, the
plan of care may become unclear, and the patient may be
at risk for poor BP control or adverse events. Success is
then dependent on coordinated care by all of these
clinicians.
Achieving BP control is just one of several proposed
intermediate outcome measures. Tighter glucose control,
as measured by hemoglobin A1c levels, is another
important intermediate outcome. Weight loss and smok-
ing cessation are other potential examples of intermedi-
ate outcome measures that require lifestyle modiﬁcation,
although to some patients, these may be important out-
comes in themselves. At ﬁrst consideration, weight loss
may seem to be a treatment that is solely under a patient’s
locus of control, but this too may be partially shared with
a healthcare clinician. The clinician, in this example,
could work jointly with the patient in setting a target
weight goal and exploring the patient-speciﬁc difﬁculties
in achieving the goal. The clinician could then take
additional actions to support the patient in achieving this
goal, such as referring the patient to a dietician; recom-
mending exercise programs or peer support groups; and
even considering psychological, pharmacological, or sur-
gical interventions, as needed, to achieve the desired
lifestyle modiﬁcation.
3.2.3. Example of Shared Accountability for Clinical Events
and Patient Outcomes
The emphasis of current outcome-focused performance
metrics has been on assessing for the occurrence of spe-
ciﬁc clinical events (e.g., death, hospital readmissions).
The aim of health care is to improve patient outcomes, yet
many factors, including patient behavior, can affect out-
comes. An example of this interplay can be found in the
Centers for Medicare and Medicaid Services’ hospital
performance metric for readmission after acute myocar-
dial infarction or heart failure. Although use of evidence-
based therapies and best-practice discharge planning can
reduce rates of hospital readmission (9), patient behavior
is also potentially inﬂuential. For example, does the pa-
tient understand and have the capacity to follow the
treatment plan, including self-care activities, such as
taking prescribed medications, implementing recom-
mended lifestyle changes, and attending scheduled clinic
visits? Does the patient understand what early warning
signs or symptoms to look for and when to promptly seek
medical attention? Can the patient easily access appro-
priate clinical advice when needed? Clinical events
attributed to individual clinicians are inﬂuenced
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2138positively or negatively by numerous factors, including
patient behavior and the systems and supports that
enable patients to effectively follow clinical recommen-
dations and discharge plans.
4. METHODOLOGICAL CHALLENGES
There are several important methodological consider-
ations when both patient and clinician have shared
accountability for PMs. These include designating the
level of measurement, assigning patients to speciﬁc clin-
ical care teams, specifying the episodes of care for longi-
tudinal process measures and clinical outcomes, ensuring
data validity, and applying appropriate risk-adjustment
methodology.
4.1. Accountability and Attribution
4.1.1. Potential Levels of Aggregation
The level of aggregation should be carefully examined
when shared accountability is considered for process and
outcome PMs. Measures of clinician performance and
outcomes may be reported at the level of individual cli-
nicians, groups of practitioners organized into clinical
practices or clinics, larger healthcare organizations (e.g.,
provider groups, hospitals, healthcare delivery systems),
health plans, employers, or communities. Similarly,
metrics assessing patient performance (e.g., adherence to
medications) can be used to examine the individual’s
behavior but could also be aggregated to the level of the
healthcare plan or the employer. Such aggregation can
assess the success of the organization or employer in
achieving prevention goals for its enrollees or employees.
There are tradeoffs in selecting any particular level of
attribution. Although measuring performance at an indi-
vidual clinician level can have the most impact on indi-
vidual patient and clinician behavior, such measurements
can be unstable and unreliable because of small numbers
of observations. Additionally, individual attribution does
not account for the potential inﬂuence of the clinical
environment. For example, if a clinic is poorly staffed or
run, this could affect the quality of care provided by all of
the clinicians working within that environment.
In contrast to individual-level measures, those aimed
at evaluating a hospital or delivery system, such as an
accountable care organization (ACO), can reﬂect care of
the entire multidisciplinary team and its patients. This
broader level of measurement can promote multidisci-
plinary, team-based, coordinated care and shared re-
sponsibility among healthcare clinicians. The challenge
with organizational metrics is instilling a sense of
ownership in all relevant individuals in the organization.
An example is the National Database of Nursing Quality
Indicators (www.nursingquality.org), which collects data
at the hospital unit level to assess the functionality andquality of the team. This approach of using data to drive
quality improvement is nonpunitive and gives the team
ownership of the outcomes. Without this, clinicians might
believe that any shortcomings are not their problem and
must be the responsibility of “others.” Another challenge
with this level of measurement is that it omits valuable
information about the clinician–patient interaction,
which can, in turn, inﬂuence patient experience, en-
gagement, and outcomes.
4.1.2. Deﬁning Patient Attribution
Regardless of the level of PM attribution selected, it is
vital that the clinicians, clinics, larger healthcare organi-
zations, health plans, employers, and communities
involved be properly deﬁned. Attribution is relatively
straightforward when the level of assessment is the single
clinician and the patient receives care from only that
clinician; however, care from a single clinician is
becoming somewhat rare in modern-day medical care.
Attribution becomes more complex when a PM reﬂects
patient care from more than one practitioner, medical
group, or hospital system (10). In a recent study, it was
found that within a single year, fee-for-service patients
were seen by a median of 7 different physicians (11).
Similarly, nearly half of Medicare patients change their
primary care physician assignment over a 2-year period.
Thus, the developers of clinician-level PMs must clearly
deﬁne which patients are considered to be “within” a
given clinician’s practice.
4.1.3. Deﬁning Parties Responsible for a PM
One must also deﬁne and determine which party should
take responsibility for which PMs. For example, it might
not be appropriate to hold a subspecialist who sees a pa-
tient in consultation for a speciﬁc procedure responsible
for that patient’s chronic prevention measures (e.g.,
breast examination, diabetic retinal examination). Alter-
natively, multiple parties may be responsible for an
outcome measure such as successful functional recovery
after hip replacement surgery, which requires the
collaboration of the surgeon, nurses, physical therapists,
pharmacist, and social worker, as well as the cooperation
and efforts of the patient to complete a rehabilitation
program. The issue of attribution becomes less relevant
when one is assessing the performance of the overall
healthcare system.
In the Physician Quality Reporting System, the Centers
for Medicare and Medicaid Services are evaluating
provider-based quality measures by using administrative
data (12). These measures include all Medicare beneﬁ-
ciaries for whom an eligible physician ﬁled at least 1
professional claim and encompass all patients of a phy-
sician’s Medicare panel. Although the same beneﬁciary
may be, and generally is, assigned to multiple physicians,
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based quality indicators applicable to that beneﬁciary in
this voluntary program.
4.1.4. Deﬁning Assessment Periods for PMs
Deﬁning the appropriate period of evaluation is an
important technical feature of PMs and should be mean-
ingful from both patient and provider perspectives. PMs
must deﬁne a discrete period (e.g., within a 12-month
period) of measurement consistent with the actual treat-
ment goals for the measure. For example, an ACC/AHA PM
for outpatient cardiac rehabilitation deﬁnes success on
the basis of “referral to” such a program before hospital
discharge. If the measure is made a shared PM, it can also
assess whether the patient decided to participate and
attended cardiac rehabilitation (or reasons for not
attending) and whether it was within the appropriate time
window (e.g., within 3 months of an event) (13). Mea-
surement of patient performance could include whether
the patient actually attended the ﬁrst appointment for
cardiac rehabilitation or, more importantly, whether the
patient not only initiated attendance, but also maintained
attendance and completed the entire program.
For outcome measures, selecting the longitudinal time
period encompassed by the measure requires similar
careful consideration. Outcome measures may include
assessments of health status, symptoms, and function as
shared-accountability measures of healthcare quality and
can provide quantitative information on the variability in
symptom control and quality of life over longitudinal
periods of time. For example, the International Con-
sortium for Health Outcomes Measurement has deﬁned a
set of recommended outcome measures, including health
status, for patients with coronary artery disease (14). For
risk adjustment of outcome measures, designation of an
appropriate reference time, before which covariates are
derived and after which outcomes are measured, is also
important.
4.2. Issues Relating to Patient Adherence and Self-Care
4.2.1. Deﬁning Adherence and Self-Care
There are methodological and psychometric challenges
speciﬁc to measuring patient adherence. Measuring pa-
tient adherence to medications involves common direct
metrics (e.g., direct observation and measurement of
serum drug levels and biological markers) and indirect
metrics (e.g., electronic medication monitoring, pill
counts, rates of prescription reﬁlls, and self- or proxy-
[surrogate/clinician] reporting) (15). Each metric has ad-
vantages, disadvantages, and arbitrary cutoffs to indicate
adherence. For example, with regard to medication tak-
ing, serum drug levels can be inﬂuenced by metabolism;
self-report measures can be biased by poor recall orinaccurate reporting resulting from patients’ desires to
please clinicians; and pill counts do not reﬂect timing of
medication taking. These measurement issues affect the
validity of adherence measures. Generally, 80% has been
considered an acceptable, albeit arbitrary, cutoff to indi-
cate adherence to medications (15,16); however, a cutoff
of 80% may be too low for some diseases/treatments
and medications (e.g., immunosuppression after heart
transplantation and in heart failure patients). Although
deﬁning taxonomy and measurement is an important
ﬁrst step, methods to measure adherence to taking
medications, following clinician recommendations, and
engaging in self-care behaviors need to be tested rigor-
ously to determine reliability, validity, and sensitivity
to change over time.
4.2.2. Challenges With Handling Patient Treatment Refusals
PMs involving adherence must also account for when
patients decline therapy. Currently, patients who opt out
of evidence-based treatments are generally not counted
in the denominator of the PM. This approach inherently
overestimates actual performance and negates the po-
tential impact that a clinician may have on patients’
acceptance of treatment plans. When a shared-
accountability framework is used, patients who refuse
treatment or tests would also be considered in the de-
nominator. With this approach, the patient’s control over
the decision to adhere is acknowledged and patient au-
tonomy is respected, while it is also recognized that the
success or failure to take a medication can be affected by
the clinician and system of care. Adding patients who
decline treatment back into the equation (i.e., in the de-
nominator) also supports shared care planning, as well as
innovative strategies to encourage shared decision mak-
ing and longitudinal patient engagement in the patient’s
health. Nevertheless, this approach may have potential
unintended adverse consequences if, because of the in-
centives generated by accountability, clinicians or
healthcare systems exclude patients who are non-
adherent. Education geared toward clinicians and the
healthcare system about the value of expanding the pool
of included patients is crucial to successful implementa-
tion of shared PMs.
It may also be valuable to determine the level at which
the problem occurs (e.g., the clinician who prescribes the
medication, the patient who decides not to take the
medication, the patient who ﬁlls the prescription but does
not take the medication). Thus, expanding inclusion
criteria (by including patients who decline therapy) as an
alternative to excluding such patients could provide cli-
nicians with a more “real-world” view of their overall
rates of success for a given shared PM. Such an inclusive
metric can also encourage development of strategies to
improve these metrics in the future.
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4.3.1. Psychosocial Factors Impacting Patient Case Mix
It is clear that, to be meaningful, PMs of outcomes require
risk adjustment for patient case mix. As was noted previ-
ously, many existing performance metrics may be inﬂu-
enced by patients. Patients, however, can differ in their
baseline likelihood of being adherent to therapeutic rec-
ommendations or participating actively in self-care stra-
tegies. Factors that can affect self-care include patient
preferences, values, culture, religion, and socioeconomic
status (i.e., education, income, and occupation); psycho-
logical factors (e.g., depression); behavioral factors (e.g.,
substance abuse); cognitive factors (e.g., health literacy,
dementia); and environmental factors (e.g., social sup-
port) (17). Collecting information on these factors may
be challenging if they are not readily available in elec-
tronic health records. Thus, when comparing clinicians or
healthcare systems, it is important, if possible, to adjust
for some of these factors; however, it also must be re-
cognized that the adjustment of PMs for socioeconomic
status may obscure important failures to provide the best
care to patients with low socioeconomic status (18,19).5. FACTORS IMPEDING OR FACILITATING THE
ADOPTION OF SHARED-ACCOUNTABILITY PMS
5.1. Health Information Systems
If PMs evolve to incorporate the concept of shared
accountability, there will need to be a way to track pa-
tients, care processes, and ultimately outcomes longitudi-
nally across multiple healthcare settings. For example,
measuring adherence to medications after an acute
event requires access to information from the discharging
institution (discharge instructions and medications),
pharmacy reﬁll information, and, ideally, follow-up
ambulatory clinic notes (to determine medication changes
or discontinuation by the outpatient care team). Although
electronic health records are being adopted in many of
these settings, electronic health records often do not
collect standardized information, nor do they allow for
easy interoperable sharing or merging of information
across settings. As a result, creating comprehensive patient
care records needed for measuring longitudinal shared-
accountability PMs will be challenging in the current
system.
In the near future, it is hoped that healthcare systems
and the government can work together on health infor-
mation exchanges that will support development of
standard nomenclature and facilitate data mapping and
sharing of information between disparate healthcare in-
formation systems, while maintaining the meaning of the
information being exchanged. Furthermore, in Stage 3 of
the meaningful use criteria (the Centers for Medicare andMedicaid Services Electronic Health Record Incentive
Programs), it has been proposed that there will be patient-
collected data, which could further support the develop-
ment and use of shared PMs (20) through clinician access
to comprehensive patient- reported outcome data and
patient access to self-management tools.
5.2. Payment Reforms, Healthcare Ownership, and ACOs
Current payment reform policies support the adoption
of concepts behind shared-accountability PMs. ACOs
are an assembly of clinicians (e.g., hospitals, health sys-
tems, physicians, nurses, pharmacists) responsible for
improving care for individuals and the health of the
population. Their goals also include reducing the rate
of growth in healthcare expenditures while advancing
outcomes and reducing costs across the healthcare con-
tinuum, including acute, ambulatory-care, and extended-
care settings. The Affordable Care Act authorized the
Centers for Medicare and Medicaid Services to contract
with ACOs to provide health care to Medicare beneﬁ-
ciaries under a Shared Savings Program that began in
January 2012 (21).
ACOs often emphasize new models of healthcare
ﬁnancial reimbursement. Rather than receiving tradi-
tional fee-for-service reimbursement (which emphasizes
that the more one does, the more one is paid), ACOs are
often reimbursed for providing comprehensive coverage
for a patient (capitated care) or speciﬁc payment for the
care of a particular disease condition for a particular
period of time (bundled payment). Although these latter
models can facilitate streamlining of care and avoiding
excessive interventions, concern also exists that they
may lead to undertreatment of patients. Given that one
of the main goals of ACOs is to improve the health
of individual patients and populations, longitudinal
shared-accountability PMs may provide a mechanism for
promoting and improving the quality of patient care
under these new healthcare reimbursement and orga-
nizational schemes (22). Finally, standardizing account-
ability PMs may affect compensation under government
and insurance reimbursement programs; this will
require aligning both federal and state laws, which are
currently complex.
6. SPECIAL ISSUES RELATING TO
PATIENT ACCOUNTABILITY METRICS
6.1. Patient PM and Accountability
A step toward developing shared accountability for
quality is the development of patient PMs. If patient-
speciﬁc PMs are developed (e.g., did the patient lose
weight, quit smoking, come in for routine follow-up
care, or take his or her medications?), there will be
questions about how these PMs are used and how
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accountability framework. Resources such as the AHA’s
“Life’s Simple 7” (23) program or the ACC’s CardioSmart
Web sites (24) provide patients with online tools to help
them identify modiﬁable risk factors for coronary artery
disease, understand why the risk factors are important,
and learn how to improve those risk factors. The AHA’s
Heart360 program (25) provides an online tool that
allows patients to track progress toward controlling their
BP, lipid, weight, and glucose levels. Although these
programs provide educational information, consideration
will need to be given to how to motivate patients to
change their behavior to achieve their health goals.
Incentives, positive or negative, have also been used to
help patients achieve PM targets. Currently, some em-
ployers penalize employees for exhibiting behaviors that
negatively impact the company’s health plan expenses
(26). Individuals who contribute to their own negative
health outcomes by smoking, being overweight or obese,
using alcohol to excess, or engaging in drug abuse have
been shown to miss more days of work, spend more time
at clinicians ’ofﬁces or treatment sites, and often do less
work when they are on the job (27,28). These employees
may be coached and given opportunities to make lifestyle
changes geared toward healthy behaviors. The Affordable
Care Act allows 50% higher premiums for patients who
continue to practice adverse health behaviors such as
smoking, and some companies have begun to charge
higher health insurance premiums to employees for
continuing to engage in behaviors that adversely affect
their health.
Alternatively, positive incentives can be implemented
to encourage patients to improve their health behaviors.
For example, American Express Company paid thousands
of employees to exercise during the summer of 2011,
giving each $200 toward their healthcare expenses simply
for walking 2.5 miles per day. Similarly, a health in-
surance company, Humana Inc., established a program
called HumanaVitality (29) to offer incentive prizes, such
as camping gear, cameras, and Caribbean hotel rooms, to
their customers who see their provider and undergo
tests to manage BP and cholesterol. Both ﬁnancial (e.g.,
lower insurance rates) and nonﬁnancial (e.g., preferred
appointment times or passes for a reserved parking area)
beneﬁts can be offered to incentivize speciﬁed healthy
behaviors.
Although extension of accountability to the patient is
an interesting and potentially exciting opportunity to
improve care, the ﬁeld of behavioral economics in medi-
cine is quite young (30-32). It must be acknowledged
that, to date, there has been limited research on the effec-
tiveness or durability of these incentive programs with
regard to patients’ treatment adherence or lifestyle modi-
ﬁcation. Furthermore, achieving meaningful behavioralchange is difﬁcult, and the possibility remains
that any such system of reward or penalty could lead
to unanticipated adverse consequences. Therefore, we
strongly encourage that novel programs that test these
strategies also include a thorough evaluation program.
6.2. Patient Financial Incentives and Unintended Consequences
No mechanism currently exists for aligning ﬁnancial
incentives for the patient and clinician. Even if align-
ment were achievable, it could impact the clinician–
patient relationship adversely. For example, ﬁnancial
rewards might motivate clinicians or patients to try
medications, diagnostic tests, or treatments for which
the evidence base on improving patient outcomes is
weak. A related concern is that the ﬁnancial incentive
may be so signiﬁcant for patients that it would lead
them to press their clinicians for treatments that
have an unfavorable balance of beneﬁts and risks. In
contrast, in circumstances in which no ﬁnancial incen-
tive is involved, the clinician might not recommend the
treatment approach, or the patient might decline to
participate in the approach. Another serious concern is
that ﬁnancial incentives and penalties could dispropor-
tionately impact certain patient populations and ulti-
mately create additional barriers to their getting needed
care or achieving better outcomes. It will be important
to conduct surveillance after the implementation of
shared PMs to identify unintended consequences of
shared PMs, including potential adverse effects on the
patient–clinician relationship. Finally, it will be impor-
tant to align the ﬁnancial interests of patients and the
healthcare system toward the common goals of the
shared PMs.7. CONCLUSION AND KEY RECOMMENDATIONS
Shared-accountability measures should be formulated
with recognition of joint ownership of care processes
and outcomes by patients, clinicians, and the healthcare
system. This approach implies that accountability for
good performance must be “owned” by multiple parties,
including not only clinicians and systems that inﬂuence
care, but also patients and their caregivers. Explicit
acknowledgment of shared accountability changes the
perception and deﬁnition of many existing PMs and
supports analyses of performance that are based on all of
the factors that can impact affect decision making and
clinical outcomes. In the development of any perfor-
mance measure, consideration should be given to patient
preferences in the evaluation of the outcomes of any
shared PM. We have outlined key concepts, measure-
ments, and considerations that need to be borne in
mind when shared-accountability PMs are developed and
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2142implemented. The following are recommendations from
the present statement:
1. The principles of shared accountability should be
considered during the process of developing, an-
alyzing, reporting, and interpreting PMs.
2. Measures of treatment and outcomes ideally should
be longitudinal in nature and should focus on
evidence-based therapies.
3. Purchasers and payers should work with stakeholders
to determine ways to apply principles of shared
accountability.
4. When considering shared accountability in PMs, one
must carefully consider the level of analysis (e.g., in-
dividual, practice, system), the timeframe of the
analysis, the attribution of subjects to a denominator
and deﬁnitions for the numerator (i.e., what consti-
tutes success), and the different care settings (e.g.,
inpatient, outpatient, home care).
5. It is important to consider examining process PMs that
retain in the denominator patients who decline or are
unable to adhere to treatment recommendations, in
addition to examining rates that exclude such pa-
tients (inasmuch as the former are more reﬂective of
actual care success rates and may be informative with
regard to clinician and system factors inﬂuencing
these rates).
6. Comparisons of shared-accountability PMs should
account for factors that affect the patient’s ability to
implement treatment recommendations and manage
self-care, such as patient preferences, culture and
beliefs, demographics, clinical characteristics, and
socioeconomic factors (e.g., education, income,
occupation); psychological, behavioral, cognitive, and
environmental factors; and community resources that
support clinician and patient efforts to achieve
desired health outcomes.
7. As a principle of shared accountability, performance
on these measures should be reported back to both
clinicians and patients in a timely fashion to facilitate
shared care management and achievement of best
outcomes.
8. Reward or penalty incentives attached to PMs should
account for all factors that inﬂuence the measure,
including clinician and system performance and pa-
tient ability to implement treatment recommenda-
tions. Ideally, the reward would be given to the
healthcare system, with the system then sharing the
reward with the multiple individuals on the team
(e.g., patients and clinicians) contributing to success.
9. Care must be taken and strategies must be imple-
mented tomonitor the impact of shared-accountability
measures to ensure that implementation does not
lead to adverse patient selection by clinicians or
decreased access to care.10. The goals of patient-based performance measurement
should be to enhance patient and family engagement
and achieve better outcomes and care experience.
Future research should both examine how the design
and implementation of these programs inﬂuences
their effectiveness and assess for potential unin-
tended consequences.STAFF
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